Monica Schmidt

Monica Schmidt

Auto-generated profile, based on publicly available information

Monica Schmidt

12 University of North Carolina , Chapel Hill

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Gastroenterology
Verified
Journal Article
Open access
PDF file
APAnne F. Peery
Anne F. Peery
SCSeth D. Crockett
Seth D. Crockett
ABAlfred S. Barritt
Alfred S. Barritt
EDEvan S. Dellon
Evan S. Dellon
SESwathi Eluri
Swathi Eluri
RSRobert S. Sandler
Robert S. Sandler
Background & Aims Gastrointestinal (GI), liver, and pancreatic diseases are a source of substantial morbidity, mortality, and cost in the United States. Quantification and statistical analyses of the burden of these diseases are important for researchers, clinicians, policy makers, and public health professionals. We gathered data from national databases to estimate the burden and cost of GI and liver disease in the United States. Methods We collected statistics on health care utilization in the ambulatory and inpatient setting along with data on cancers and mortality from 2007 through 2012. We included trends in utilization and charges. The most recent data were obtained from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. Results There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses of hemorrhoids in the ambulatory setting in a year. Functional and motility disorders resulted in nearly 1 million emergency department visits in 2012; most of these visits were for constipation. GI hemorrhage was the most common diagnosis leading to hospitalization, with >500,000 discharges in 2012, at a cost of nearly $5 billion dollars. Hospitalizations and associated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disease have increased during the last 20 years. In 2011, there were >1 million people in the United States living with colorectal cancer. The leading GI cause of death was colorectal cancer, followed by pancreatic and hepatobiliary neoplasms. Conclusions GI, liver and pancreatic diseases are a source of substantial burden and cost in the United States.

29 February 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
VSVarun Saxena
Varun Saxena
FKFarrukh M. Koraishy
Farrukh M. Koraishy
MSMeghan E. Sise
Meghan E. Sise
JLJoseph K. Lim
Joseph K. Lim
MSMonica Schmidt
Monica Schmidt
HTHcv‐ Target
Hcv‐ Target

1 May 2015 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MSMonica L. Schmidt
Monica L. Schmidt
ABA. Sidney Barritt
A. Sidney Barritt
EOEric S. Orman
Eric S. Orman
PHPaul Hayashi
Paul Hayashi
Background & Aims It is not clear whether evidence-based recommendations for inpatient care of patients with cirrhosis are implemented widely or are effective in the community. We investigated changes in inpatient outcomes and associated features over time. Methods By using the Healthcare Cost and Utilization Project, National Inpatient Sample, we analyzed 781,515 hospitalizations of patients with cirrhosis from 2002 through 2010. We compared data with those from equal numbers of hospitalizations of patients without cirrhosis and patients with congestive heart failure (CHF), matched for age, sex, and year of discharge. The primary outcome was a change in discharge status over time. Factors associated with outcomes were analyzed by Poisson modeling. Results The mortality of patients with and without cirrhosis, and patients with CHF, decreased over time. The absolute decrease was significantly greater for patients with cirrhosis (from 9.1% to 5.4%) than for patients without cirrhosis (from 2.6% to 2.1%) or patients with CHF (from 2.5% to 1.4%) (P < .01). However, relative decreases were similar for patients with cirrhosis (41%) and patients with CHF (44%). For patients with cirrhosis, the independent mortality risk ratio decreased steadily to 0.50 by 2010 (95% confidence interval, 0.48–0.52), despite patients’ increasing age and comorbidities. Hepatorenal syndrome, hepatocellular carcinoma, variceal bleeding, and spontaneous bacterial peritonitis were associated with a higher mortality rate, but the independent mortality risks for each decreased steadily. Sepsis was associated strongly with increased mortality, and the risk increased over time. Conclusions Among patients with cirrhosis in the United States, inpatient mortality decreased steadily from 2002 through 2010, despite increases in patient age and medical complexity. Improvements in cirrhosis care may have contributed to increases in patient survival beyond those attributable to general improvements in inpatient care. Further improvements might require an increased use of proven therapies and the development of new treatments—particularly for sepsis.

1 December 2009 in Anaerobe
Verified
Journal Article
Closed access
MSMonica L. Schmidt
Monica L. Schmidt
PGPeter H. Gilligan
Peter H. Gilligan

19 June 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JFJordan J Feld
Jordan J Feld
RMRaoel Maan
Raoel Maan
SZStefan Zeuzem
Stefan Zeuzem
AKAlexander Kuo
Alexander Kuo
DNDavid R. Nelson
David R. Nelson
MFMichael W. Fried
Michael W. Fried
Background. Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice. Methods. Hepatitis C Virus Therapeutic Registry and Research Network is an international, prospective observational study evaluating patients treated in usual clinical practice. Patients with GT3 HCV were analyzed to assess predictors of treatment response and adverse events using descriptive statistics and multivariable logistic regression. Results. Treatment outcomes were available for 197 patients treated with SOF and ribavirin (RBV), with or without peginterferon, including 54% with cirrhosis and 49% who failed prior therapy. Of 178 patients treated with SOF/RBV, 60% achieved SVR at 12 weeks (SVR12), compared with 84% of 19 patients treated with SOF/peginterferon/RBV. For patients treated with SOF/RBV, the SVR12 rate was 58% in treatment-naive patients with cirrhosis, and 42% in those with cirrhosis who failed prior therapy. In noncirrhotic patients, SVR12 rates were 89% in treatment-naive and 88% in treatment-experienced patients. After controlling for age and sex, absence of cirrhosis (odds ratio [OR], 6.4; 95% confidence interval [CI], 2.78–14.74), albumin levels ≥3.2 g/dL (OR, 12.48; 95% CI, 3.86–40.33), and platelet count >105 cells/µL (OR, 7.44; 95% CI, 3.51–15.78) were associated with greater odds of SVR12. Conclusions. SVR rates were acceptable in patients with GT3 HCV without cirrhosis; however, in those with cirrhosis, treatment with SOF/RBV was suboptimal, highlighting the need for new therapies for this population.

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
APAnne F. Peery
Anne F. Peery
MSMonica Schmidt
Monica Schmidt
MKMark Koruda
Mark Koruda